ENCORE: Arikayce improves respiratory symptoms in M. avium complex lung disease

ORLANDO — In patients newly diagnosed with Mycobacterium avium complex lung disease, amikacin liposome inhalation suspension Arikayce plus multidrug therapy for 12 months improved respiratory symptoms, according to results presented here.“Not only did this regimen improve the quality of life of the participants, but it made a significant microbiologic impact as well,” Charles L.